View Single Post
Old 10-29-2013, 12:40 PM   #2
donocco
Senior Member
 
Join Date: Oct 2013
Posts: 468
Re: MM-302 with Advanced Breast Cancer

I dont know if this is repetitive info but I did some quick
research on the drug. MM302 is a liposomal form of Doxorubicin (Adriamycin). The fatty liposome particles are coated with anti Her2neu protein particles, so the liposomes containing the Adriamycin go straight to the Her2Neu carrying breast cancer cells. Once inside the cancer cells, the liposome breaks up and the Adriamycin is released in the cancer cells hopefully killing it. The idea is to avoid the heart toxicity of Doxorubicin (Adriamycin) as the muscle cells in the heart have low levels of Her2Neu protein.

A possible dose might be 40mg per square meter once every 4 weeks. The main side effects seem to be constipation (53%), fatigue (69%) and decreased appetite (46%). Interestingly there was no mention of hand-foot syndrome (so far) which is a main side effect of Doxyl, the FDA approved liposomal Doxorubicin. Doxyl liposomes are not coated with anti-Her2Neu antibody and are less cancer cell specific.

Hope this helps a bit.

Paul
donocco is offline   Reply With Quote